Study ID | All‐cause mortality | Diabetes‐related complications | Diabetes‐related mortality | HbA1c | Health‐related quality of life | FBG | Insulin sensitivity | Socioeconomic effects | Severe/serious adverse events |
Timmers 2016 | NR | NR | NR | Glycosylated haemoglobin A1c (IO) | NR | Fasting blood glucose (IO) | "Insulin Sensitivity (HOMA‐IR) and Substrate Kinetics Assessed by Hyperinsulinemic‐Euglycemic Clamp" (IO) | NR | ND |
Thazhath 2016 | NR | NR | NR | Glycosylated haemoglobin A1c (IO) | NR | Fasting blood glucose (IO) | NR | NR | ND |
Brasnyo 2011 | NR | NR | NR | NR | NR | NR | HOMA‐IR: "The values of homeostasis model of assessment for insulin resistance and related to B‐cell function (HOMAIR and HOMAb, respectively) were calculated as in Nagaretani et al.and Matthews et al., respectively" (IO) | NR | ND |
aIn addition to the definition of endpoint measurement, description of who measured the outcome (AO: adjudicated outcome measurement; IO: investigator‐assessed outcome measurement; SO: self‐reported outcome measurement). FBG: fasting blood glucose, HbA1c: glycosylated haemoglobin A1c, HOMA‐IR: homeostasis model of assessment for insulin resistance, ND: not defined, NR: not reported. |